ARTICLE | Clinical News
Supinoxin: Ph IIa started
March 3, 2017 5:39 PM UTC
Rexahn began an open-label, U.S. Phase IIa trial to evaluate Supinoxin in up to 50 patients who have failed prior therapies. ...
BCIQ Company Profiles
BCIQ Target Profiles
Rexahn began an open-label, U.S. Phase IIa trial to evaluate Supinoxin in up to 50 patients who have failed prior therapies. ...
BCIQ Company Profiles
BCIQ Target Profiles
BCIQ Company Profiles
BCIQ Target Profiles